TESARO Company Profile (NASDAQ:TSRO)

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

TESARO, Inc. (NASDAQ:TSRO) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.52) by $0.30. The firm earned $29.50 million during the quarter, compared to analysts' expectations of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. TESARO's revenue for the quarter was down 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.28) earnings per share. View TESARO's Earnings History.

TESARO is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for TESARO.

22 analysts have issued 12-month price targets for TESARO's stock. Their predictions range from $120.00 to $236.00. On average, they anticipate TESARO's share price to reach $169.82 in the next twelve months. View Analyst Ratings for TESARO.

Here are some recent quotes from research analysts about TESARO stock:

• 1. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (10/17/2017)
• 2. Cann analysts commented, "These results are an analysis of the phase I/II TOPACIO study of niraparib plus pembrolizumab in combination with pembrolizumab (Keytruda) in patients with triple negative breast cancer (TNBC) or ovarian cancer. Safety and efficacy were presented from both the dose-finding portion as well as the dose-expansion portion of the study. We believe these data released today support a path forward for Tesaro in the TNBC setting with Zejula. TNBC is a particularly challenging setting. There are many studies from numerous drug sponsors underway and TNBC, but there is no established reference standard for this disease." (9/8/2017)
• 3. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
• 4. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
• 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

TESARO saw a decline in short interest in the month of September. As of September 29th, there was short interest totalling 6,767,191 shares, a decline of 28.5% from the September 15th total of 9,459,637 shares. Based on an average trading volume of 570,698 shares, the days-to-cover ratio is currently 11.9 days. Approximately 17.9% of the company's stock are short sold.

Some companies that are related to TESARO include Kite Pharma (KITE), Exelixis (EXEL), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Sarepta Therapeutics (SRPT), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA) and Ultragenyx Pharmaceutical (RARE).

TESARO's management team includes the folowing people:

• David M. Mott, Independent Chairman of the Board
• Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
• Leon O. Moulder Jr., Chief Executive Officer, Director
• Timothy R. Pearson, Chief Financial Officer, Executive Vice President
• Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
• Grant C. Bogle, Senior Vice President, Chief Commercial Officer
• Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
• Lawrence M. Alleva, Independent Director
• James O. Armitage M.D., Independent Director

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TESARO stock can currently be purchased for approximately $113.60.